1Dolton M J, Ray JE, Chen SC, et al. Multieenter study of voricon- azole pharmacokinetics and therapeutic drug monitoring [ J ]. Anti- microb Agents Chemother,2012,56 (9) :4793 - 4799.
2Lee S, Kim BH, Nam WS, et al. Effect of CYP2CI 9 Polymorphism on the Pharmacokinetics of Voriconazole After Single and Multiple Doses in Healthy Volunteers[J]. J Clin Pharmaeol,2012,52(2) : 195 - 203.
3Weiler S, Zoller H, Graziadei I, et al. Altered pharmacokinetics of voriconazole in a patient with liver cirrhosis[ J]. Antimicrob Agents Chemother,2007,51 ( 9 ) : 3459 - 3460.
4Hope WW. Population pharmaeokineties of voriconazole in adults [ J]. Antimicrob Agents Chemother,2012,56 ( 1 ) :526 - 531.
5Michael C, Teichert J, Preiss R. Determination of voliconazole in human plasma and saliva using high-performance liquid chromatog- raphy with fluorescence detection [ J]. J Chromatogr Sci,2008,865 (1-2) :74 -80.
6Lin D, Li G, Chen L. Determination of voriconazole in human plasma by HPLC-ESI-MS and application to pharmaeokinetic study[ J]. J Chromatogr Sci ,2013,51 (6) :485 -489.
7Yanmda T,Mino Y,Yagi T, et al. Rapid simultaneous determina- tion of voriconazole and its N-oxide in human plasma using an isocratichigh-performance liquid chromatography method and its clinical application[ J]. Clin Biochem ,2012,45 ( 1-2 ) : 134 - 138.
8Wissen CP,Burger DM,Verweij PE, et al. Simultaneous determina- tion of the azoles vorieonazole, posaconazole, isavuconazole,itracon- azole and its metabolite hydroxy-itraconazole in human plasma by reversedphase ultra-perfolxnance liquid chromatography with ultravio- let detection [ J ]. J Chromatogr Sci ,2012,887-888:79 - 84.
9Langman LJ, Boakye-Agyeman F. Measurement of voriconazole in serumand plasma[ J ]. Clin Biochem ,2007,40(18) : 1378 - 1385.
10Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications[ J]. Antimicrob Agents Chemother,2009,53 ( 1 ) :24 - 34.
